HYPERFIBRINOGENEMIA IN RELATION TO GLYCEMIC STATUS AND DYSLIPIDEMIA IN TYPE 2 DIABETES MELLITUS AND CORONARY HEART DISEASE
PDF

How to Cite

Ali, S., Khan, M., & Khan, M. (2015). HYPERFIBRINOGENEMIA IN RELATION TO GLYCEMIC STATUS AND DYSLIPIDEMIA IN TYPE 2 DIABETES MELLITUS AND CORONARY HEART DISEASE. KHYBER MEDICAL UNIVERSITY JOURNAL, 7(3). Retrieved from https://www.kmuj.kmu.edu.pk/article/view/14236

Abstract

OBJECTIVES: To determine plasma fibrinogen level in type 2 diabetic
patients with and without coronary heart disease (CHD) and to find
relationship of fibrinogen with glycemic control and lipid profile in
these patients.
METHODS: A cross-sectional / analytical study was performed among
the outdoor and indoor patients visiting Khyber Teaching Hospital and
Hayatabad Medical Complex, Peshawar, Pakistan. The study consisted
of two groups. Group A was comprised of 100 type 2 diabetic patients
without CHD and group B was comprised of 100 type 2 diabetic patients
with CHD. Biochemical analysis of samples was carried out in
the Research laboratory of Biochemistry Department, Khyber Medical
College, Peshawar. Plasma fibrinogen level was measured by clotting
method and statistical analysis was done on SPSS 19 soft ware.
RESULTS: Mean plasma fibrinogen level was 413.44±139.75 mg/dL
& 478.63±165.97 mg/dL was observed in group-A & group-B respectively
(p<0.05). Mean fasting blood sugar was 175.61±59.13 mg/dL &
213.80±91.62 mg/dL in group-A & group-B respectively (p<0.05). Mean
HbA1C in group-A and group-B was 8.308±3.03% & 10.166±3.452%
respectively (p<0.05). A strong positive association of fibrinogen was
seen with serum triglycerides (p<0.01), total cholesterol (p<0.05) and
body mass index (p<0.01).
CONCLUSION: Fibrinogen levels are elevated in type 2 diabetic patients
with and without coronary heart disease. Moreover, hyperfibrinogenemia
is associated with serum cholesterol, serum triglycerides and BMI
in these patients.
KEY WORDS: Fibrinogen (MeSH); Diabetes Mellitus (MeSH); Hemoglobin
A, Glycosylated (MeSH); Body Mass Index (MeSH); Hyperlipidemias
(MeSH); Cholesterol (MeSH); Triglycerides (MeSH)

PDF

References

MN Chatergee, Rana Shinde. Text Book

of Medical Biochemistry (seventh edition).

Arjuna YN, Jaypee Brothers Medical Publishers,

New Delhi, 2007, P 321

Pai KJ, Pischon T, Jing MA, Manson JE,

Susan EH, Joshipura K, et al. Inflammatory

markers and the risk of coronary heart

disease in men and women. N Engl Med

; 351: 2599-610.

Bombed AS. A study of plasma Fibrinogen

level in Type-2 Diabetes Mellitus and its

relation to Glycemic control. Indian J

Hematol Blood Transfuse 2012; 28(2):

-108.

Shera AS, Basit A, Fawwad A, Hakeem R,

Ahmedani MY, Hydrie MZ, et al. Pakistan

National Diabetes Survey: prevalence of

glucose intolerance and associated factors

in the Punjab Province of Pakistan. Prim

Care Diabetes 2010; 4: 79-83.

Skyler J. Diabetic complications: the importance

of glucose control. Endocrinol

Metab Clin North Am 1996; 25: 243-54.

Davis TM, Fortun P, Mulder J, Davis WA,

Bruce DG. Silent myocardial infarction

and its prognosis in a community based

cohort of type 2 diabetic patients; the

Fremantle diabetes study. Diabetologia

;47(3):395-9.

Rubin R, Strayer DDS, Rubin E. Rubin’s Pathology:

Clinicopathological Foundations

of Medicine. Maryland: Lippincott Williams

and Wilkins, 2001, p. 549.

Sanidas EA, Vauranakis M, Papaioannou

TG, Carlier S, Syros G, Dangas G, et al.

Study of atheromatous plaque using intravascular

ultrasound. Hellenic J Cardiol

; 49: 415-21.

Vogiatzi G, tousoulis D, Stefanadis C. The

role of oxidative stress in atherosclerosis,

Hellenic J Cardiol 2009; 50: 402-9.

Kampoli A-M, Tousoulis D, Antoniades

C, Siasos G, Stefanadis C. Biomarkers of

premature atherosclerosis. Trends Mol

Med 2009;15:323-32.

Papageorgiou N, Tousoulis D, Siasos G,

Stefandis C. Is fibrinogen a marker of

inflammation in coronary artery diseases?

Hellenic J Cardiol 2010; 51: 1-9.

De Maat MP. Effects of diet, drugs and

genes on plasma fibrinogen level. Ann N

Y Acad Sci 2001; 936: 509-21.

Ilyas S, Waheed U, Saboor M. Coagulation

abnormalities in diabetes mellitus. J Public

Health Biol Sci 2013; 2(4):308-12.

Lee AJ, Lowe GD, Smith WC, Tunstall-Pedoe

H. Plasma fibrinogen in women:

relationship with oral contraception, the

menopause and hormone replacement

therapy. Br J Haematol 1993; 83(4):

-21.

Nadeem A, Naveed AK, Hussain MM, Raza

SI. Correlation of inflammatory markers

with type 2 diabetes mellitus in Pakistani

patients. J Postgrad Med Inst 2013; 27(3):

-73.

Laurens N, Koolwijhk P, de Maat MP. Fibrin

structure and wound healing. J Thromb

Haemost 2006; 4: 932-9.

Naito M, Funaki C, Hayashi T, Yamada

K, Asai K, Yoshimine N et al. Substrate

bound fibrinogen, fibrin and other cell attachment-

promoting proteins as a scaffold

for cultured vascular smooth musckle cell.

Atherosclerosis 1992; 96: 227-34.

Schulze MB, Rimm EB, Li T, Rifai N,

Stamfer MJ, Hu FB. C-reactive protein

and incident cardiovascular events among

men with diabetes. Diabete Care 2004;

(4): 889-94.

Dandona P, Alijada A. A rational approach

to pathogenesis and treatment of type 2

diabetes mellitus, insulin resistance inflammation

and atherosclerosis. Am J Cardiol

; 90: 27-33.

Kafle DR, Shrestha P. Study of fibrinogen

in patients with diabetes mellitus. Nepal

Med Coll J 2010; 12(1):34-7.

Cristobal JJR, Grote CA, Mercade PT,

Santos JMP, Sendra EP, Lloret AM et al.

Randomised clinical trial of an intensive

intervention in the primary care setting

of patients with high plasma fibrinogen in

the primary prevention of cardiovascular

disease. BMC Research Notes 2012; 5:

-32.

Guidelines on fibrinogen assays. Br J Haematol

: 121 (3): 396-404.

Sjohoim A, Nyström T. Endothelial inflammation

in insulin resistance. Lancet 2005;

: 610-2.

Venkataramana G, Indira P; Rao DVM.

Changes of plasma total proteins, albumin

and fibrinogen in type 2 diabetes mellitus:

A pilot study. Indian Journal of Basic &

Applied Medical Research; June 2013:

Issue-7, Vol.-2, P. 679-85.

Fuster V, Badimon L, Badimon J. Chesebro

J. The pathogenesis of coronary artery disease

and the acute coronary syndromes.

N Engl J Med. 1992; 326: 242-50.

Lyer MU, Desai P. Assesment of C-reactive

protein and fibrinogen level in type

diabetes mellitus. Biomed Res 2010;21: 208-13.

Alzahrani SH, Ajjan RA. Coagulation and

fibrinolysis in diabetes. Diab Vasc Dis Res

; (4): 260-73.

Mohamed RA, Abdrabo AA, Muddathir

AM. The Association between Microalbuminuria

and Plasma Fibrinogen Levels in

type 2 diabetic Sudanese patients. American

Journal of Research Communication,

, 1(10): 69-75.

Stratmann B, Tschoepe D. Atherogenesis

and atherothrombosis-focus on diabetes

mellitus. Best Pract Res Clin Endocrinol

Metab 2009; 23: 291-303.

Martin-Timon I, Collantes SC, Galindo AS,

Gomez FJC. Type 2 diabetes and cardiovascular

disease: Have all risk factors the

same strength? World J Diabetes 2014;

(4): 444-70.

Hong LF, Li XL, Luo SH, Guo YL, Zhu

CG, Qing P, et al. Association of fibrinogen

with severity of stable coronary artery

disease in patients with type 2 diabetes

mellitus. Disease Markers 2014, Article

ID 485687, 8 pages. http:// dx. Doi.

Org/10.1155/2014/485687.

Bosevski M, Bosevska G, Stojanovska L.

Influence of fibrinogen and C-RP on progression

of peripheral arterial disease in

type 2 diabetes: a preliminary report. Cardiovascular

Diabetology 2013; 12: 29-34.

Rana JS, Cote M, Despris JP, Sandhu MS,

Talmud PJ, Ninio E, et al. Inflammatory

biomarker and the prediction of coronary

events among people at intermediate risk

the EPIC–Norfolk prospective population

study. Heart 2009; 95: 1682-7.

Madhu SV, Kumar V, Gambhir JK. Plasma

fibrinogen in patients with type 2 diabetes

mellitus with and without macrovascular

disease and its relationship with endothelial

function, carotid intima media thickness

and dyslipidemia. Int J Diabetes In Developing

Countries. 2011; 31(3): 143-8.

Bembdi AS. A study of plasma fibrinogen

level in type-2 diabetes mellitus and its

relation to glycemic control. Indian J Hematol

Blood Transfus 2012; 28(2): 105-8.

Lowe G, Woodward M, Hillis G, Rumley

A, Li Q, Harrap S, et al. Circulating inflammatory

markers and the risk of vascular

complications and mortality in people with

type 2 diabetes and cardiovascular disease

or risk factors: The ADVANCE Study.

Diabetes 2014;63(3): 1115-23.

Lawlor DA, Smith GD, Rumley A, Lowe

GDO, Ebrahim S. Association of fibrinogen

and C-reactive protein with prevalent

and incident coronary heart disease are

attenuated by adjustment for confounding

factors. British Women’s Heart and Health

study. Thromb Haemost 2005; 93: 955-63.

Theodore Mazzone. Intensive glucose

lowering and cardiovascular disease

prevention in diabetes: Reconciling the

recent clinical trial data. Circulation 2010;

: 2201-11.

Mohan V, Venkatraman JV, Pradeepa R.

Epidemiology of cardiovascular disease

in type 2 diabetes: the Indian scenario. J

Diabetes Sci Technol 2010; 4(1): 158-70.

Stec JJ, Silbershatz H, Tofler GH, Matheney

TH, Sutherland P, Lipinska L, et al. Association

of fibrinogen with cardiovascular

risk factors and cardiovascular disease

in the Framingham off spring population.

Circulation 2000; 102: 1634-8.

Ernst E, Resch KL. Fibrinogen as a cardiovascular

risk factor. A meta analysis and

review of the literature. Ann Intern Med

; 118: 956-63.

Kaptoge S, Angelantonio ED, Pennells L,

Wood AM, Ian R, Peri G, et al. C-reactive

protein, fibrinogen and cardiovascular

disease prediction. New Engl J Med 2012;

: 1310-20.

Work published in KMUJ is licensed under a

 Creative Commons Attribution-NonCommercial 2.0 Generic License.

Creative Commons License

Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.